Apollon Wealth Management’s Amedisys AMED Stock Holding History

Apollon Wealth Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-68	Closed	-$14K	–	183
2020 Q2	$14K	Buy	+68	New	+$12.7K	0.01%	431

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Apollon Wealth Management's AMED Position: Q3 2020 in Review

Apollon Wealth Management sold out of Amedisys (AMED) in Q3 2020, closing a stake of 68 shares — an estimated $14K sold.

Apollon Wealth Management first reported a position in AMED in Q2 2020 and held it in 1 quarter. The position peaked at $14K in Q2 2020. 397 funds tracked by Wall St. Rank hold AMED as of Q3 2020.

Apollon Wealth Management reported no remaining Amedisys position as of Q3 2020 after selling out during the quarter.
Apollon Wealth Management sold 68 Amedisys shares in Q3 2020, an estimated $14K.
Apollon Wealth Management first reported a position in Amedisys in Q2 2020 and held it in 1 quarter.
Apollon Wealth Management's Amedisys position peaked at $14K in Q2 2020.
397 funds tracked by Wall St. Rank held Amedisys as of Q3 2020.

Based on Apollon Wealth Management's 13F filing for Q3 2020, filed 3 Nov 2020.